HU9202432D0 - Improved cyclodextrine based erythropoiethine preparatives - Google Patents

Improved cyclodextrine based erythropoiethine preparatives

Info

Publication number
HU9202432D0
HU9202432D0 HU922432A HU243292A HU9202432D0 HU 9202432 D0 HU9202432 D0 HU 9202432D0 HU 922432 A HU922432 A HU 922432A HU 243292 A HU243292 A HU 243292A HU 9202432 D0 HU9202432 D0 HU 9202432D0
Authority
HU
Hungary
Prior art keywords
erythropoiethine
preparatives
cyclodextrine
improved
erythropoietin
Prior art date
Application number
HU922432A
Other languages
English (en)
Other versions
HUT62198A (en
HU218213B (hu
Inventor
Frank J Konings
Marcus Noppe
Jean L Mesens
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10670074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HU9202432(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HU9202432D0 publication Critical patent/HU9202432D0/hu
Publication of HUT62198A publication Critical patent/HUT62198A/hu
Publication of HU218213B publication Critical patent/HU218213B/hu

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
HU9202432A 1990-01-29 1991-01-25 Ciklodextrin tartalmú eritropoietin készítmények és eljárás előállításukra HU218213B (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909001987A GB9001987D0 (en) 1990-01-29 1990-01-29 Improved cyclodextrin based erythropietin formulation
PCT/EP1991/000173 WO1991011200A1 (en) 1990-01-29 1991-01-25 Improved cyclodextrin based erythropoietin formulation

Publications (3)

Publication Number Publication Date
HU9202432D0 true HU9202432D0 (en) 1992-10-28
HUT62198A HUT62198A (en) 1993-04-28
HU218213B HU218213B (hu) 2000-06-28

Family

ID=10670074

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9202432A HU218213B (hu) 1990-01-29 1991-01-25 Ciklodextrin tartalmú eritropoietin készítmények és eljárás előállításukra

Country Status (20)

Country Link
US (1) US5376632A (hu)
EP (1) EP0513072B1 (hu)
JP (1) JP2997052B2 (hu)
KR (1) KR0183445B1 (hu)
AT (1) ATE107518T1 (hu)
AU (1) AU648061B2 (hu)
CA (1) CA2074820C (hu)
DE (1) DE69102627T2 (hu)
DK (1) DK0513072T3 (hu)
ES (1) ES2059115T3 (hu)
FI (1) FI105012B (hu)
GB (1) GB9001987D0 (hu)
HU (1) HU218213B (hu)
IE (1) IE65209B1 (hu)
IL (1) IL97019A (hu)
NO (1) NO304728B1 (hu)
NZ (1) NZ236938A (hu)
PT (1) PT96593B (hu)
WO (1) WO1991011200A1 (hu)
ZA (1) ZA91620B (hu)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4126984A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, gut vertraeglichen arzneimitteln fuer infusions- oder injektionszwecke
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
US5494901A (en) * 1993-01-05 1996-02-27 Javitt; Jonathan C. Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
IL116085A (en) * 1994-12-16 1999-12-31 Ortho Pharma Corp Spray dried erythropoietin
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
CA2252374C (en) 1996-04-19 2007-08-07 Alpha Therapeutic Corporation A process for viral inactivation of lyophilized blood proteins
US5754937A (en) 1996-05-15 1998-05-19 Stackpole Limited Hi-density forming process
ATE222118T1 (de) * 1997-03-18 2002-08-15 Roche Diagnostics Gmbh Pharmazeutische kombinationspräparate enthaltend erythropoietin und eisenpräparate
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
AU757896B2 (en) * 1998-09-02 2003-03-13 Allergan, Inc. Preserved cyclodextrin-containing compositions
US20040152664A1 (en) * 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
IL145816A0 (en) * 1999-04-09 2002-07-25 Ortho Mcneil Pharm Inc Pharmaceutical compositions of erythropoietin
WO2002011753A1 (fr) * 2000-08-04 2002-02-14 Chugai Seiyaku Kabushiki Kaisha Preparations proteiniques a injecter
US20060235366A1 (en) * 2000-12-20 2006-10-19 Fox Hollow Technologies, Inc. Method of evaluating a treatment for vascular disease
US20020146409A1 (en) * 2001-01-30 2002-10-10 Herring Steven W. Methods for stabilizing lyophilized blood proteins
KR20040018434A (ko) * 2001-07-09 2004-03-03 야마노우치세이야쿠 가부시키가이샤 서방성 주사제용 조성물 및 이의 제조방법
DE10228049A1 (de) 2002-06-24 2004-01-15 Merck Patent Gmbh Flüssige Zubereitung enthaltend Oligopeptide
US7459435B2 (en) * 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US7459436B2 (en) * 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
MXPA05013398A (es) 2003-06-10 2006-03-09 Lg Life Sciences Ltd Solucion estable acuosa de eritropoyetina de origen humano, que no contiene albumina de suero.
EP1537876A1 (en) * 2003-12-01 2005-06-08 BioGeneriX AG Erythropoietin solution formulation
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US20110236902A1 (en) * 2004-12-13 2011-09-29 Tyco Healthcare Group Lp Testing a patient population having a cardiovascular condition for drug efficacy
US7794413B2 (en) * 2005-04-19 2010-09-14 Ev3, Inc. Libraries and data structures of materials removed by debulking catheters
CU23317A1 (es) * 2005-07-22 2008-10-22 Ct De Investigacia N Y Desarro Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central
EA200900571A1 (ru) 2006-10-20 2009-12-30 Айкос Корпорейшн Композиции chk1 ингибиторов
DK2590666T3 (en) * 2010-07-06 2017-07-17 Augustinus Bader TOPICAL APPLICATION OF ERYTHROPOIETIN FOR USE IN THE TREATMENT OF DAMAGE OF THE CORNS
US10328152B2 (en) 2011-06-16 2019-06-25 Nayan Patel Method for stabilization and delivery of therapeutic molecules
US11583584B1 (en) * 2015-10-28 2023-02-21 Coherus Biosciences, Inc. Stable protein compositions and methods of their use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
JPS60258125A (ja) * 1984-06-06 1985-12-20 Hayashibara Biochem Lab Inc 蛋白性生理活性物質を含有する水溶性乾燥物
JPS6191131A (ja) * 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
US4920214A (en) * 1986-04-16 1990-04-24 American Maize-Products Company Process for producing modified cyclodextrins
EP0308181A1 (en) * 1987-09-14 1989-03-22 Novo Nordisk A/S Trans-mucosal delivery formulations and a method for preparation thereof
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5068227A (en) * 1989-01-18 1991-11-26 Cyclex, Inc. Cyclodextrins as carriers

Also Published As

Publication number Publication date
PT96593A (pt) 1991-10-15
DE69102627D1 (de) 1994-07-28
IL97019A (en) 1997-07-13
NZ236938A (en) 1992-07-28
GB9001987D0 (en) 1990-03-28
NO922990L (no) 1992-07-29
DK0513072T3 (da) 1994-08-01
WO1991011200A1 (en) 1991-08-08
HUT62198A (en) 1993-04-28
FI923402A0 (fi) 1992-07-28
ES2059115T3 (es) 1994-11-01
HU218213B (hu) 2000-06-28
US5376632A (en) 1994-12-27
CA2074820C (en) 2003-10-14
EP0513072B1 (en) 1994-06-22
FI923402A (fi) 1992-07-28
EP0513072A1 (en) 1992-11-19
ZA91620B (en) 1992-10-28
NO922990D0 (no) 1992-07-29
JPH05503700A (ja) 1993-06-17
JP2997052B2 (ja) 2000-01-11
DE69102627T2 (de) 1994-11-03
IE910286A1 (en) 1991-07-31
IE65209B1 (en) 1995-10-04
CA2074820A1 (en) 1991-07-30
IL97019A0 (en) 1992-03-29
AU7149791A (en) 1991-08-21
PT96593B (pt) 2001-06-29
FI105012B (fi) 2000-05-31
KR0183445B1 (en) 1999-05-01
AU648061B2 (en) 1994-04-14
ATE107518T1 (de) 1994-07-15
NO304728B1 (no) 1999-02-08

Similar Documents

Publication Publication Date Title
HU9202432D0 (en) Improved cyclodextrine based erythropoiethine preparatives
EP0214647A3 (en) Inclusion complexes of 7-isopropoxy-isoflavone and cyclodextrins, process for their preparation and pharmaceutical preparations containing these complexes
HU9300685D0 (en) Method for producing crystallic momethazone-furoate-monohydrate and pharmaceutical preparatives containing it
GR3032732T3 (en) Amido-3-pyrazole derivatives, process for their preparation and pharmaceutical compositions containing them.
HUT66717A (en) Biodegradable compositions comprising starch derivatives, methods of making the compositions, and articles made from said composition
HUT61554A (en) Process for producing 2,8-dioxabicyclo/3.2.1/octane derivatives and pharmaceutical compositions comprising same
ATE132518T1 (de) Hilfstoffzusammensetzungen in fester form dispergierbar in wasserigen medien und verfahren zur herstellung davon
ZA908069B (en) Inclusion complexes with silybinin,their preparation and their pharmaceutical compositions containing them
HUT65418A (en) Process for producing inclusion compounds of nimesulide with cyclodextrins and pharmaceutical preparatives containing them
HUP9601321A2 (en) Substituted (benzyloxy)-carbonyl-guanidine derivatives, process for producing them, pharmaceutical compositions containing them their use as pharmaceutical compositions or diagnostica, and the use of the said compds.
NO922682L (no) Polysakkaridblanding, fremgangsmaate for dens fremstillingog anvendelse derav
CA2036337A1 (fr) Derives de la 20,21-dinoreburnamenine, leur procede de preparation et les nouveaux intermediaires ainsi obtenus, leur application comme medicaments et les compositions les renfermant
MD679F1 (en) Inclusion complex of N-ethoxycarbonyl-3-morpholinsydnonimine or salts thereof with cyclodextrin or its derivatives, preparation thereof and pharmaceutical compositions containing them, method of preparation thereof and treatment method
AU8972591A (en) Novel 15-nitro-2beta,3beta-dihydro- and 15-nitro-2beta,3beta,6,7-tetrahydrotabersonine derivatives, pharmaceutical compositions containing them and process for preparing same
NZ237944A (en) Certain 8-hydroxy-bicyclo(7.3.1)tridec-4-ene 2,6-diyne-13-one derivatives: hexacarbonyl dicobalt complexes as intermediates: preparation thereof and pharmaceutical compositions
PT99146A (pt) Processo para a preparacao de complexos de inclusao com silibinina e de composicoes farmaceuticas que os contem
IT1241459B (it) Composizioni farmaceutiche per la somministrazione rettale di calcitonina
SG25294G (en) Pyrrolo-pyridine derivatives, process and compositions.